1,2,3,4-tetrahydro-(9H)-pyrido<3,4-b>indole-1-spiro-1'-cyclopentane | 42282-67-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1,2,3,4-tetrahydro-(9H)-pyrido<3,4-b>indole-1-spiro-1'-cyclopentane
• 英文别名: 3',4'-dihydro-spiroindole>；1,2,3,4-tetrahydro-β-carboline-1-spirocyclopentane；2',3',4',9'-tetrahydrospiro[cyclopentane-1,1'-pyrido[3,4-b]indole]；1-Spirocyclopentano-1,2,3,4-tetrahydro-β-carbolin；2,3,4,9-tetrahydro-spiro[β-carboline-1,1'-cyclopentane]；Apuptihjcfkkdk-uhfffaoysa-；spiro[2,3,4,9-tetrahydropyrido[3,4-b]indole-1,1'-cyclopentane]
• CAS: 42282-67-7
• 化学式: C₁₅H₁₈N₂
• 分子量: 226.321
• InChiKey: APUPTIHJCFKKDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2,3,4-tetrahydro-(9H)-pyrido<3,4-b>indole-1-spiro-1'-cyclopentane 、 碘甲烷 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以72%的产率得到2-methyl-1,2,3,4-tetrahydro-(9H)-pyrido<3,4-b>indole-1-spiro-1'-cyclopentane
  参考文献：
  名称：

  1,2,3,4-四氢-（9 H）-吡啶并[3,4- b ]吲哚的合成与分析

  摘要：

  在一个锅中，通过胰蛋白酶和环烷酮的缩合，在多磷酸盐酯的存在下，在一个锅中进行1,2,3,4-四氢-（9 H）-吡啶并[3,4- b ]吲哚衍生物的合成。中等至低收率的催化剂，醛醇缩合是主要产物。色胺与环酮的反应也通过亚胺中间体在两个阶段进行，并带有质子催化，得到高产率的四氢-β-咔啉8-14。使用甲基碘在二甲基亚砜-碳酸钾中的高产率获得了四氢-β-咔啉的2-甲基衍生物15-21。

  DOI：

  10.1002/jhet.5570300214
• 作为产物：
  描述：

  色胺盐酸盐 在 acetate buffer 、 硫酸 作用下， 反应 168.33h， 生成 1,2,3,4-tetrahydro-(9H)-pyrido<3,4-b>indole-1-spiro-1'-cyclopentane
  参考文献：
  名称：

  Pictet-Spengler reactions of Tryptamine and tryptophan with cycloalkanones and ketonicMannich bases

  摘要：

  DOI：

  10.1007/bf00809161

文献信息

• NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1724264A1

  公开（公告）日：2006-11-22

  The present invention relates to a compound of formula (I) wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substituent, etc,; n is 0, or an integer of from 1 to 10, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. The compound of formula (I), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof has an inhibitory activity against cysteine protease, and it is useful for the prophylaxis and/or treatment of a cysteine protease-related disease such as osteoporosis, etc.

  本发明涉及一种具有以下式（I）的化合物，其中Y和Z各自独立地为N或C；环A为碳环基团或杂环基团；环B为含有至少一个氮原子的杂环基团；R为氢原子、取代基等；n为0，或为1至10的整数，其盐、溶剂合物、N-氧化物或前药。具有式（I）的化合物，其盐、溶剂合物、N-氧化物或前药对半胱氨酸蛋白酶具有抑制活性，对于预防和/或治疗半胱氨酸蛋白酶相关疾病如骨质疏松症等是有用的。
• Two‐in‐One Strategy for Palladium‐Catalyzed C−H Functionalization in Water
  作者：Huiying Zeng、Zemin Wang、Chao‐Jun Li

  DOI：10.1002/anie.201813391

  日期：2019.2.25

  Transition metal catalyzed C−H functionalizations have been developed as powerful methods for C−C bond formations. Directing groups, removable directing groups, traceless directing groups, and transient directing groups (TDGs) have been successfully used to improve the reaction efficiencies. For the development of greener and more sustainable methods, C−H functionalization using a TDG that also serves

  过渡金属催化的CH官能化已被开发为形成CC键的有力方法。导向基团，可移动的导向基团，无痕导向基团和瞬态导向基团（TDG）已被成功地用于提高反应效率。为了开发更绿色，更可持续的方法，研究了使用TDG的CH功能化，该TDG还可以用作水性溶剂中的试剂。使用酮在水中的钯催化的色胺类胺的CH-H官能化成功生成了四氢-β-咔啉，其四级碳中心位于C1。讨论了氘标记实验以提供对该机理的深入了解。吡啶的C2位也通过该策略成功地官能化。
• Novel tricyclic heterocycle compound
  申请人：Ohmoto Kazuyuki

  公开号：US20060154944A1

  公开（公告）日：2006-07-13

  The present invention relates to the compound represented by formula (I) A—X—Y-Z-B  (I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.

  本发明涉及由式(I)A—X—Y-Z-B所表示的化合物（其中A是可能具有取代基的环状基团；X是单键或间隔物；Y是单键或间隔物；Z是单键或间隔物；B是可能具有取代基的碳氢基团或环状基团），其盐、溶剂化物或前药。该式(I)化合物、其盐、溶剂化物或前药可用作预防和/或治疗由压力引起的疾病的药物。
• Antistress drug and medical use thereof
  申请人：Ohmoto Kazuyuki

  公开号：US20070099938A1

  公开（公告）日：2007-05-03

  The compound represented by formula (I) (wherein ringA is cyclic group which may have a substituent(s), Q is alkyl which may have a substituent(s) or cyclic ring which may have a substituent(s), ringD is cyclic ring which may have a substituent(s), W is a single bond or a spacer of which main chain has an atom number of 1-4, Y is a spacer of which main chain has an atom number of 1-4.), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof Since the compounds represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

  化合物的分子式为（I）（其中环A是一个可以有取代基的环状基团，Q是一个可以有取代基或环状基团的烷基，环D是一个可以有取代基的环状基团，W是一个单键或具有1-4个原子数的主链的间隔键，Y是具有1-4个原子数的主链的间隔键），其盐，N-氧化物或溶剂化物，或其前药。由于分子式（I）所代表的化合物，其盐，N-氧化物或溶剂化物，或其前药具有对MBR的亲和力，因此它们对于预防和/或治疗由压力引起的疾病是有用的。
• Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
  申请人：Ohmoto Kazuyuki

  公开号：US20080249154A1

  公开（公告）日：2008-10-09

  A compound represented by formula (I) (wherein ring A is a nitrogen-containing ring which may have a substituent(s), E is a binding bond or a spacer of which main chain has an atom number of 1-8, Q is a hydrogen atom, a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s).), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. Since the compounds of the present invention represented by formula (I), a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof have the affinity to MBR, they are useful for the prevention and/or treatment for disease caused by stress.

  化合物的化学式为(I)，其中环A是含氮环，可能有取代基；E是一个键合或一个带有1-8个原子的主链间隔物；Q是氢原子、一个可带有取代基的碳氢基团或一个可带有取代基的环状基团。该化合物的盐、N-氧化物、溶剂化合物或前药也在本发明的范围内。由于本发明化合物（I）、其盐、N-氧化物或溶剂化合物或前药具有与MBR的亲和性，它们可用于预防和/或治疗由压力引起的疾病。

表征谱图